Myeloproliferative Neoplasms (MPNs) [Excluding CML] - Page 2

Indolent & Smoldering Systemic Mastocytosis
- HEM0044
  Phase II/III BLU-263 in Indolent Systemic Mastocytosis
  PI: Shomali
  Sponsor: Blueprint Medicines Corporation

Aggressive Systemic Mastocytosis/Mast Cell Leukemia
- CD30-
- HEM0061
  Phase II Open-Label 2-Arm Study Evaluating BLU-263 as Monotherapy & in Combo w/ Azaclidine, in KIT Altered Hematologic Malignancies
  PI: Gotlib
  Sponsor: Blueprint Medicines Corporation

- HEM0034
  Phase II Avapritinib (BLU-285) KIT Mutation-targeted TKi in Advanced Systemic Mastocytosis
  PI: Gotlib
  Sponsor: Blueprint Medicines Corp.
  1st Priority

- HEM0045
  Phase II CGI-9486 as a Single Agent in Advanced Systemic Mastocytosis
  PI: Gotlib
  Sponsor: Cogent Biosciences, Inc.

KEY
- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Enrollment on Hold
- Extension Study
- Immunotherapy